The present invention provides a medical dressing article and a method of manufacturing the same, which comprises: (a) a first layer comprised of polycaprocaptone fibers having a PCL fiber diameter of 0.5 μm and 2.9 μm; (b) a second layer, deposited directly on the first layer, including a mixture of polycaprolactone and poloxamer fibers (PCL and POX fibers) wherein a PCL and POX fiber diameter is between 0.1 μm and 4 μm; and (c) a third layer, deposited directly on the second layer, further comprising a mixture of gelatin and silver nitrate (AgNO.sub.3).

The present invention provides a liquid bandage containing peptide anti-inflammatory active ingredient and a preparation method thereof, which relates to the technical field of medical materials. The liquid bandage comprises film-forming agents; one or more plasticizers, comprising glycerin; one or more anti-inflammatory substances, comprising oligopeptide with an amino acid sequence of Leu-Leu-Phe-Thr-Thr-Gln; and solvent, comprising deionized water. The liquid bandage can promote the expression of interleukin 10 (IL-10) and inhibit the expressions of interleukin 6 (IL-6) and tumor necrosis factor (TNF-α). Peptide anti-inflammatory active ingredient can produce good anti-inflammatory activity. Further, the liquid bandage can enhance the close contact between gel and the injured skin surface, increase the cleanliness of the wound surface, and can increase a clearance rate of inflammatory cells.

The present invention provides a liquid bandage containing peptide anti-inflammatory active ingredient and a preparation method thereof, which relates to the technical field of medical materials. The liquid bandage comprises film-forming agents; one or more plasticizers, comprising glycerin; one or more anti-inflammatory substances, comprising oligopeptide with an amino acid sequence of Leu-Leu-Phe-Thr-Thr-Gln; and solvent, comprising deionized water. The liquid bandage can promote the expression of interleukin 10 (IL-10) and inhibit the expressions of interleukin 6 (IL-6) and tumor necrosis factor (TNF-α). Peptide anti-inflammatory active ingredient can produce good anti-inflammatory activity. Further, the liquid bandage can enhance the close contact between gel and the injured skin surface, increase the cleanliness of the wound surface, and can increase a clearance rate of inflammatory cells.

The present invention relates to a wound dressing composition that is capable of gelling upon contact with a fluid derived from a human or animal body, and which is able to maintain the integrity of the gel for a period of time that is longer than about 24 hours.

The present invention relates to a multi-use hemostatic composition and a method for producing the same, and more particularly, to a technique relating to a multi-use a hemostatic agent in which a first component having a modified anionized substituent and a second component that is a polymer having adhesiveness are included to provide improved hemostatic ability and biocompatibility so as to have applicability into surgery, laparoscopy, and various surgical procedures.

The present invention relates to a multi-use hemostatic composition and a method for producing the same, and more particularly, to a technique relating to a multi-use a hemostatic agent in which a first component having a modified anionized substituent and a second component that is a polymer having adhesiveness are included to provide improved hemostatic ability and biocompatibility so as to have applicability into surgery, laparoscopy, and various surgical procedures.

The present invention relates to methods and compositions for rendering a surface resistant to bio-film formation by a combination of an antimicrobial agent, an organic hydroxy acid, lubricious biomedical polymer and solvent. The invention provides for compositions which may be used to render surfaces bio-film resistant, articles having bio-film resistant surfaces, and methods for their preparation. The present invention may be advantageously applied to medical articles as well as articles used in non-medical contexts, such as child care or food preparation.

A dissolvable medical device for protecting a corneal surface and providing lubrication and hydration to the corneal surface during ophthalmic surgery comprising: a polymeric film has sufficient dimensions to substantially cover a cornea when applied to an eye, wherein the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive polymers after applying the polymeric film to the eye and the polymeric film provides more effective corneal surface protection relative to a saline treatment based on Mean Green Fluorescence Index test (demonstrates corneal damage) during a simulated surgery. In addition, a kit for use in ophthalmic surgical procedures comprises 1) the at least one dissolvable medical device and 2) at least one viscosurgical viscoelastic or at least one ophthalmoscopic surgical contact lens.

A dissolvable medical device for protecting a corneal surface and providing lubrication and hydration to the corneal surface during ophthalmic surgery comprising: a polymeric film has sufficient dimensions to substantially cover a cornea when applied to an eye, wherein the polymeric film comprising one or more mucoadhesive polymers. The polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive polymers after applying the polymeric film to the eye and the polymeric film provides more effective corneal surface protection relative to a saline treatment based on Mean Green Fluorescence Index test (demonstrates corneal damage) during a simulated surgery. In addition, a kit for use in ophthalmic surgical procedures comprises 1) the at least one dissolvable medical device and 2) at least one viscosurgical viscoelastic or at least one ophthalmoscopic surgical contact lens.

A dissolvable medical device for placing on the outer exposed surface of the eye to heal the corneal wound comprising of: a polymeric film has sufficient dimensions to substantially cover a cornea when applied to an eye, wherein the polymeric film comprising one or more mucoadhesive polymers, wherein the polymeric film dissolves between 15 minutes to 120 minutes to release the mucoadhesive polymers, wherein the dissolved polymeric film is not impeding visualization of ocular tissue while maintaining a protective film on outer surface of the eye.